FELBAMATE

Post-LOE

felbamate

ANI Pharmaceuticals

ANDAORALSUSPENSION

Approved

Jun 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FELBAMATE (felbamate) by ANI Pharmaceuticals is mechanism of action the mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Approved for epilepsy, anemia. First approved in 2017.

Drug data last refreshed 21h ago

$0.0BPart D

Mechanism of Action

Mechanism of Action The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Felbamate is effective in mice and rats in the maximal…

Pharmacologic Class:

Anti-epileptic Agent

Indications (2)

Worked on FELBAMATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.